IMTXW
Income statement / Annual
Last year (2023), immatics biotechnologies GmbH's total revenue was $54.00 M,
a decrease of 68.76% from the previous year.
In 2023, immatics biotechnologies GmbH's net income was -$96.99 M.
See immatics biotechnologies GmbH’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
| Operating Revenue |
$54.00 M
|
$172.83 M
|
$34.76 M
|
$31.25 M
|
$18.45 M
|
$3.77 M
|
| Cost of Revenue |
$118.66 M |
$106.78 M |
$87.57 M |
$67.08 M |
$40.09 M |
$33.97 M |
| Gross Profit |
-$64.67 M |
$66.05 M |
-$52.81 M |
-$35.83 M |
-$21.64 M |
-$30.20 M |
| Gross Profit Ratio |
-1.2 |
0.38 |
-1.52 |
-1.15 |
-1.17 |
-8.01 |
| Research and Development
Expenses |
$118.66 M
|
$106.78 M
|
$87.57 M
|
$67.09 M
|
$40.09 M
|
$33.97 M
|
| General & Administrative
Expenses |
$38.20 M
|
$36.12 M
|
$33.81 M
|
$34.19 M
|
$11.76 M
|
$7.67 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$38.20 M
|
$36.12 M
|
$33.81 M
|
$34.19 M
|
$11.76 M
|
$7.67 M
|
| Other Expenses |
-$1.14 M |
-$26,000.00 |
-$332,000.00 |
-$303,000.00 |
-$385,000.00 |
-$3.46 M |
| Operating Expenses |
$155.72 M |
$142.88 M |
$121.05 M |
$100.97 M |
$51.46 M |
$38.18 M |
| Cost And Expenses |
$155.72 M |
$142.88 M |
$121.05 M |
$100.97 M |
$51.46 M |
$38.18 M |
| Interest Income |
$13.85 M |
$9.42 M |
$5.68 M |
$850,000.00 |
$790,000.00 |
$507,000.00 |
| Interest Expense |
$831,000.00 |
$8.28 M |
$1.73 M |
$289,000.00 |
$170,000.00 |
$16,000.00 |
| Depreciation &
Amortization |
$7.23 M
|
$6.84 M
|
$5.47 M
|
$4.12 M
|
$3.85 M
|
$2.25 M
|
| EBITDA |
-$88.93 M
|
$50.04 M
|
-$83.56 M
|
-$64.44 M
|
-$29.16 M
|
-$31.73 M
|
| EBITDA Ratio |
-1.65 |
0.27 |
-2.17 |
-2.06 |
-1.54 |
-8.42 |
| Operating Income Ratio
|
-1.88
|
0.17
|
-2.48
|
-2.23
|
-1.79
|
-9.13
|
| Total Other
Income/Expenses Net |
$4.73 M
|
$12.08 M
|
-$7.04 M
|
-$142.13 M
|
$526,000.00
|
$2.05 M
|
| Income Before Tax |
-$96.99 M |
$42.04 M |
-$93.34 M |
-$229.62 M |
-$32.49 M |
-$32.36 M |
| Income Before Tax Ratio
|
-1.8
|
0.24
|
-2.68
|
-7.35
|
-1.76
|
-8.58
|
| Income Tax Expense |
$0.00 |
$4.55 M |
$1.73 M |
-$268,000.00 |
-$746,000.00 |
-$2.97 M |
| Net Income |
-$96.99 M |
$37.51 M |
-$95.06 M |
-$229.35 M |
-$31.74 M |
-$31.44 M |
| Net Income Ratio |
-1.8 |
0.22 |
-2.73 |
-7.34 |
-1.72 |
-8.34 |
| EPS |
-1.2 |
0.55 |
-1.51 |
-4.78 |
-0.5 |
-0.5 |
| EPS Diluted |
-1.2 |
0.54 |
-1.51 |
-4.78 |
-0.5 |
-0.5 |
| Weighted Average Shares
Out |
$80.55 M
|
$67.22 M
|
$62.91 M
|
$48.00 M
|
$62.91 M
|
$62.91 M
|
| Weighted Average Shares
Out Diluted |
$80.55 M
|
$68.82 M
|
$62.91 M
|
$48.00 M
|
$62.91 M
|
$62.91 M
|
| Link |
|
|
|
|
|
|
